2014: The Year of Immunotherapy in Sarcoma?
Posted: Mon Jun 01, 2015 7:45 pm
How long did it take for the rabies vacine to help us today ,with out computers and medical links might I add?
Wow .Let us all be thankful for today's information wave.
Rabies history from 2300 before Christ. ( BC)
http://www.123helpme.com/history-of-rab ... ?id=154021
http://sarcomahelp.org/articles/immunot ... comas.html
The conclusive statement of "Making 2014 the Immunotheraphy in Sarcoma"
"However, these approaches will not develop by themselves. It has taken 30 years for immunotherapy to arrive at this point and the other disease groups have an undeniable head start. We need to develop sarcoma specific immunotherapeutic strategies from target identification, to a better characterization of the microenvironment as well as practical strategies for moving these new therapies to the clinic. The pharmaceutical industry is frequently skeptical of supporting clinical trials in sarcoma so we need to be proactive in producing research that clearly demonstrates where these strategies are likely to be successful. "
As we know too well, cancer research takes time. If we want immunotherapies to benefit sarcoma patients in the future, we need to start now. We should all make 2014 the year of sarcoma immunotherapy.
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
http://www.nejm.org/doi/full/10.1056/nejmoa1305133
Wow .Let us all be thankful for today's information wave.
Rabies history from 2300 before Christ. ( BC)
http://www.123helpme.com/history-of-rab ... ?id=154021
http://sarcomahelp.org/articles/immunot ... comas.html
The conclusive statement of "Making 2014 the Immunotheraphy in Sarcoma"
"However, these approaches will not develop by themselves. It has taken 30 years for immunotherapy to arrive at this point and the other disease groups have an undeniable head start. We need to develop sarcoma specific immunotherapeutic strategies from target identification, to a better characterization of the microenvironment as well as practical strategies for moving these new therapies to the clinic. The pharmaceutical industry is frequently skeptical of supporting clinical trials in sarcoma so we need to be proactive in producing research that clearly demonstrates where these strategies are likely to be successful. "
As we know too well, cancer research takes time. If we want immunotherapies to benefit sarcoma patients in the future, we need to start now. We should all make 2014 the year of sarcoma immunotherapy.
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
http://www.nejm.org/doi/full/10.1056/nejmoa1305133